{"id":"clopenthixol","rwe":[{"pmid":"40839626","year":"2025","title":"Sexual dysfunctions related to use of antipsychotics: A protocol for a systematic review and meta-analysis.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"39613826","year":"2024","title":"Sex differences of fall-risk-increasing drugs in the middle-aged and elderly: a descriptive, cross-sectional study of FDA adverse event reporting system.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"30000827","year":"2006","title":"Zuclopenthixol.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"31303314","year":"2019","title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","finding":"","journal":"Lancet (London, England)","studyType":"Clinical Study"},{"pmid":"28414209","year":"2017","title":"Polypharmacological in Silico Bioactivity Profiling and Experimental Validation Uncovers Sedative-Hypnotic Effects of Approved and Experimental Drugs in Rat.","finding":"","journal":"ACS chemical biology","studyType":"Clinical Study"}],"tags":[{"label":"clopenthixol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 6","category":"target"},{"label":"HTR6","category":"gene"},{"label":"N05AF02","category":"atc"},{"label":"Active","category":"status"},{"label":"Psychotic disorder","category":"indication"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"sordinol","offLabel":[],"synonyms":["clopenthixol hydrochloride","clopenthixol HCl","clopenthixol","chlorpenthixol","sordinol"],"timeline":[],"approvals":[],"brandName":"Sordinol","ecosystem":[{"indication":"Psychotic disorder","otherDrugs":[{"name":"acetophenazine","slug":"acetophenazine","company":"Schering"},{"name":"chlorpromazine","slug":"chlorpromazine","company":"Glaxosmithkline"},{"name":"fluphenazine","slug":"fluphenazine","company":""},{"name":"fluphenazine decanoate","slug":"fluphenazine-decanoate","company":"Bristol Myers Squibb"}],"globalPrevalence":null}],"mechanism":{"target":"5-hydroxytryptamine receptor 6","targets":[{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"}],"modality":"Small Molecule","drugClass":"clopenthixol","explanation":"Think of it like a volume control on a radio. The 5-hydroxytryptamine receptor 6 is like a dial that helps control how much of a certain signal is sent to the brain. By blocking this dial, Sordinol helps to reduce the amount of signal sent, which can help to calm the brain and reduce symptoms of psychosis.","oneSentence":"Sordinol works by blocking the 5-hydroxytryptamine receptor 6, which helps to regulate mood and behavior.","technicalDetail":"Clopenthixol acts as a selective antagonist at the 5-HT6 receptor, which is involved in the regulation of dopamine release and has been implicated in the pathophysiology of psychotic disorders."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4397","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CLOPENTHIXOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CLOPENTHIXOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:12:11.844461","biosimilars":[],"competitors":[{"drugName":"chlorprothixene","drugSlug":"chlorprothixene","fdaApproval":"1967-06-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"thiothixene","drugSlug":"thiothixene","fdaApproval":"1967-07-24","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"clopenthixol","indications":{"approved":[{"name":"Psychotic disorder","source":"DrugCentral","snomedId":69322001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"chlorprothixene","brandName":"chlorprothixene","genericName":"chlorprothixene","approvalYear":"1967","relationship":"same-class"},{"drugId":"thiothixene","brandName":"thiothixene","genericName":"thiothixene","approvalYear":"1967","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05766007","phase":"","title":"Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-08-01","conditions":["Schizophrenia","Psychosis","Mania","Pregnancy","Drug Exposure in Utero","Drug Exposure Via Breast Milk","Antipsychotic Agents","Breastfeeding"],"enrollment":125,"completionDate":"2026-06-30"},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":["Treatment Resistant Schizophrenia","Treatment Resistant Bipolar Disorder"],"enrollment":40,"completionDate":"2027-12-20"},{"nctId":"NCT07152184","phase":"PHASE2","title":"Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-01-01","conditions":["Patient With Schizophrenia Spectrum Disorder","NLM Classification WM 203, Psychology:Schizophrenic Psychology","Schizophrenia Spectrum and Other Psychotic Disorders"],"enrollment":288,"completionDate":"2032-02-01"},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":["Schizophrenia","Schizophrenia and Disorders With Psychotic Features","Schizoaffective Disorders"],"enrollment":21,"completionDate":"2016-06-22"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":["Psychotic Disorders","Schizophrenia","Schizoaffective Disorder","Bipolar Disorder","Diabetes Mellitus, Type 2"],"enrollment":725489,"completionDate":"2012-12"},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":["Psychosis Nos/Other"],"enrollment":104,"completionDate":"2015-11"},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":["Schizophrenia"],"enrollment":100,"completionDate":"2012-12"},{"nctId":"NCT00206960","phase":"NA","title":"Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia","status":"COMPLETED","sponsor":"Birte Glenthoj","startDate":"1998-01","conditions":["Schizophrenia"],"enrollment":56,"completionDate":"2010-09"},{"nctId":"NCT00767715","phase":"PHASE4","title":"A Study in the Treatment of Acute Mania","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2004-10","conditions":["Bipolar Disorder"],"enrollment":11,"completionDate":"2005-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"0A432D932A","CHEBI":"CHEBI:59115","INN_ID":"1315","UMLSCUI":"C0009026","ChEMBL_ID":"CHEMBL53904","KEGG_DRUG":"D02613","DRUGBANK_ID":"DB13841","PUBCHEM_CID":"5311507","SNOMEDCT_US":"387566002","SECONDARY_CAS_RN":"633-59-0","MESH_DESCRIPTOR_UI":"D003006"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":186,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AF02","allCodes":["N05AF02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"40839626","title":"Sexual dysfunctions related to use of antipsychotics: A protocol for a systematic review and meta-analysis.","journal":"PloS one"},{"date":"2024 Nov 29","pmid":"39613826","title":"Sex differences of fall-risk-increasing drugs in the middle-aged and elderly: a descriptive, cross-sectional study of FDA adverse event reporting system.","journal":"Scientific reports"},{"date":"2006","pmid":"30000827","title":"Zuclopenthixol.","journal":""},{"date":"2019 Sep 14","pmid":"31303314","title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","journal":"Lancet (London, England)"},{"date":"2017 Jun 16","pmid":"28414209","title":"Polypharmacological in Silico Bioactivity Profiling and Experimental Validation Uncovers Sedative-Hypnotic Effects of Approved and Experimental Drugs in Rat.","journal":"ACS chemical biology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sordinol (Clopenthixol) is a small molecule drug belonging to the clopenthixol class, targeting the 5-hydroxytryptamine receptor 6. It is used to treat psychotic disorders. The commercial status of Sordinol is unclear, and it may be patented or have generic manufacturers. Key safety considerations are not well-documented. As a result, its use should be approached with caution.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}